CTCAE system class | Methylphenidate No of participants with ≥1 event (%) | Placebo No of participants with ≥1 event (%) |
Ear and labyrinth | 2 (13.3) | 0 |
Eye | 1 (6.7) | 3 (42.9) |
Gastrointestinal | 7 (46.7) | 1 (14.3) |
General disorders | 2 (13.3) | 2 (28.6) |
Infections and infestations | 1 (6.7) | 1 (14.3) |
Investigations | 2 (13.3) | 0 |
Metabolism and nutrition | 1 (6.7) | 0 |
Musculoskeletal | 5 (33.3) | 1 (14.3) |
Nervous system | 10 (66.7), 1 SAE (6.7) | 3 (42.9) |
Psychiatric | 5 (33.3) | 3 (42.9) |
Respiratory | 7 (46.7) | 6 (85.7) |
Reproductive system and breast | 1 (6.7) | 0 |
Skin and subcutaneous tissue | 4 (26.7) | 1 (14.3) |
Vascular disorders | 2 (13.3) | 0 |
Any | 14 (93.3) | 7 (100.0) |
CTCAE, Common Terminology Criteria for Adverse Events; SAE, serious AE.